Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC - 2024-04-25T10:32:28.000Z

The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028. Read this story